InflaRx N.V. filed a Form 6-K with the SEC on November 3, 2026, disclosing plans to initiate two Phase 2 clinical trials of izicopan in ANCA-associated vasculitis settings in 2027, along with the formation of an AAV and renal disease Advisory Board.

Key Highlights

  • Two Phase 2 trials planned: InflaRx N.V. intends to begin two Phase 2 trials of izicopan, its oral C5a receptor (C5aR) inhibitor, in 2027, with first data readout anticipated in 2028.
  • Renal vasculitis study: A randomized, placebo-controlled Phase 2 study in patients with AAV with renal involvement is planned, with trial site initiation expected to begin in early 2027.
  • Open-label trial: A second open-label Phase 2 trial targeting newly diagnosed or relapsing AAV patients in need of remission induction therapy is also planned for 2027 initiation.
  • GC replacement goal: The open-label trial will assess izicopan's ability to replace glucocorticoid treatment during remission induction, according to the filing.
  • Advisory Board formed: The company disclosed it has formed an AAV and renal disease Advisory Board comprised of internationally recognized experts across vasculitis, nephrology, autoimmunity, and immune-mediated kidney disease.
  • Capital Markets Day: The disclosures accompanied a press release titled "InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day," issued November 3, 2026.

InflaRx Outlines Izicopan Development Strategy in ANCA-Associated Vasculitis

According to the Form 6-K filed November 3, 2026, InflaRx N.V. (NASDAQ:IFRX), headquartered in Jena, Germany, announced its intention to advance izicopan, described in the filing as an oral C5a receptor (C5aR) inhibitor, through two separate Phase 2 trials in ANCA-associated vasculitis (AAV), with both trials set to begin in 2027. The company stated its goal is to provide "multiple datasets demonstrating differentiated efficacy and safety in multiple ANCA-associated vasculitis settings."

The first planned trial is described as a randomized, placebo-controlled Phase 2 study in patients with AAV with renal involvement, referred to in the filing as renal vasculitis. Trial site initiation is expected to begin in early 2027. According to the filing, the trial design has been optimized to assess potential benefits related to renal function and renal injury recovery when tested in comparison to placebo, both on top of standard of care. The second trial is an open-label Phase 2 study in newly diagnosed or relapsing AAV patients, intended to assess whether izicopan can replace glucocorticoid treatment during remission induction. First data readouts from these trials are anticipated in 2028, the company disclosed.

The filing also disclosed that InflaRx has established an AAV and renal disease Advisory Board, described as comprised of internationally recognized experts in vasculitis, nephrology, autoimmunity, and immune-mediated kidney disease. The Advisory Board is expected, according to the filing, to provide independent expert perspectives on disease biology, patient care, clinical development, and the evolving treatment environment. The company noted the Advisory Board's input will help inform its efforts to advance complement-targeted therapeutic candidates. The filing contains forward-looking statements, which the company identifies as subject to known and unknown risks and uncertainties, and for which it assumes no obligation to update.

What Was Disclosed

InflaRx N.V. filed a Form 6-K on November 3, 2026, disclosing plans for two Phase 2 trials of izicopan in AAV settings to begin in 2027, with data expected in 2028, and the formation of a new AAV and renal disease Advisory Board.